{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:11:08Z","timestamp":1790349068617,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ncl.2025.05.017","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:53:00Z","timestamp":1756900380000},"page":"781-797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune-Mediated Neuropathies Other Than Typical Chronic Inflammatory Demyelinating Polyradiculoneuropathy-Multifocal Motor Neuropathy, Autoimmune Nodopathies, Anti-Myelin Associated Glycoprotein Neuropathy, Chronic Inflammatory Sensory Polyradiculoneuropathy, and Chronic Ataxic Neuropathy with Ophthalmoplegia, M-Protein, Agglutinin, and Disialosyl Antibodies"],"prefix":"10.1016","volume":"43","author":[{"given":"Amro M.","family":"Stino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ncl.2025.05.017_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27046","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach","volume":"63","author":"Stino","year":"2021","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.017_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mus.27954","article-title":"Anti-myelin-associated glycoprotein neuropathy: where do we stand?","volume":"68","author":"Stino","year":"2023","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.017_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.10182","article-title":"Patterns of nerve conduction abnormalities in POEMS syndrome","volume":"26","author":"Sung","year":"2002","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.ncl.2025.05.017_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","article-title":"Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy","volume":"85","author":"Nobile-Orazio","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.017_bib5","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000119","article-title":"Complement activity is associated with disease severity in multifocal motor neuropathy","volume":"2","author":"Vlam","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp-2019-321977","article-title":"IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS","volume":"91","author":"Shelly","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"10.1016\/j.ncl.2025.05.017_bib7","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1212\/WNL.0b013e3181ff94c2","article-title":"Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.017_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"Joint Task Force of the","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.017_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.48.5.1218","article-title":"Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy","volume":"48","author":"Van Es","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.05.017_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577953","article-title":"Plexus MRI helps distinguish the immune-mediated neuropathies MADSAM and MMN","volume":"371","author":"Beecher","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.017_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","article-title":"A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy","volume":"18","author":"Hahn","year":"2013","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.017_bib12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/mus.25107","article-title":"Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy","volume":"54","author":"Katzberg","year":"2016","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.ncl.2025.05.017_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/jnnp-2014-310280","article-title":"Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?","volume":"87","author":"Cocito","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2025.05.017_bib14","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1007\/s00415-019-09475-x","article-title":"Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy","volume":"266","author":"Herraets","year":"2019","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.410300312","article-title":"Immunosuppressive treatment in multifocal motor neuropathy","volume":"30","author":"Feldman","year":"1991","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.017_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.017_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jns.12141","article-title":"Rasch-built overall disability scale for multifocal motor neuropathy (MMN-RODS((c)))","volume":"20","author":"Vanhoutte","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.017_bib19","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/mus.26051","article-title":"Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM","volume":"57","author":"Martinez-Thompson","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.017_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.58.4.615","article-title":"Axonal multifocal motor neuropathy without conduction block or other features of demyelination","volume":"58","author":"Katz","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.017_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11910-023-01264-4","article-title":"Growing spectrum of autoimmune nodopathies","volume":"23","author":"Gupta","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.017_bib22","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1212\/WNL.0000000000004773","article-title":"Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies","volume":"90","author":"Burnor","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.017_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp-2023-331378","article-title":"Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort","volume":"95","author":"Broers","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"24","key":"10.1016\/j.ncl.2025.05.017_bib24","doi-asserted-by":"crossref","first-page":"e2392","DOI":"10.1212\/WNL.0000000000012932","article-title":"Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes","volume":"97","author":"Shelly","year":"2021","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.ncl.2025.05.017_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.0000000000006625","article-title":"Ultrastructural mechanisms of macrophage-induced demyelination in CIDP","volume":"91","author":"Koike","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.017_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000817","article-title":"Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy","volume":"7","author":"Appeltshauser","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.017_bib27","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001098","article-title":"Clinical and laboratory features in anti-NF155 autoimmune nodopathy","volume":"9","author":"Martin-Aguilar","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.017_bib28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/acn3.51775","article-title":"Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody","volume":"10","author":"Liu","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2025.05.017_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awy134","article-title":"Subacute nodopathy with conduction blocks and anti-neurofascin 140\/186 antibodies: an ultrastructural study","volume":"141","author":"Vallat","year":"2018","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.ncl.2025.05.017_bib30","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.017_bib31","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000771","article-title":"Contactin-1 autoimmunity: serologic, neurologic, and pathologic correlates","volume":"7","author":"Dubey","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jns.12565","article-title":"Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response","volume":"28","author":"Bresciani","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.ncl.2025.05.017_bib33","article-title":"Successful autologous hematopoietic stem cell transplantation in a refractory anti-Caspr1 antibody nodopathy","author":"Afanasiev","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.017_bib34","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/brain\/awac418","article-title":"Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage","volume":"146","author":"Appeltshauser","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.017_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0000000000001195","article-title":"Pan-Neurofascin autoimmune nodopathy - a life-threatening, but reversible neuropathy","volume":"36","author":"Appeltshauser","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ncl.2025.05.017_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577725","article-title":"Anti-MAG neuropathy: from biology to clinical management","volume":"361","author":"Steck","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"Pt 4","key":"10.1016\/j.ncl.2025.05.017_bib37","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12342","article-title":"Limitations in daily activities and general perception of quality of life: long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy","volume":"24","author":"Campagnolo","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.017_bib39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.20678","article-title":"Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins","volume":"35","author":"Lupu","year":"2007","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2025.05.017_bib41","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/ene.15553","article-title":"Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: clinical, hematological and neurophysiological correlations during 2 years of follow-up","volume":"29","author":"Parisi","year":"2022","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.017_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16164","article-title":"Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: a phase 1 study to identify the maximum tolerated dose","volume":"31","author":"Stino","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2025.05.017_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/jns.12547","article-title":"IgM anti-MAG(+\/-) peripheral neuropathy (IMAGiNe) study protocol: an international, observational, prospective registry of patients with IgM M-protein peripheral neuropathies","author":"Hamadeh","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"10.1016\/j.ncl.2025.05.017_bib44","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/01.WNL.0000142507.12763.58","article-title":"Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia","volume":"63","author":"Sinnreich","year":"2004","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.ncl.2025.05.017_bib45","doi-asserted-by":"crossref","first-page":"e2078","DOI":"10.1212\/WNL.0000000000011792","article-title":"Expanding the spectrum of chronic immune sensory polyradiculopathy: CISP-plus","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.ncl.2025.05.017_bib46","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:20:13Z","timestamp":1761592813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0733861925000362"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.05.017","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-Mediated Neuropathies Other Than Typical Chronic Inflammatory Demyelinating Polyradiculoneuropathy-Multifocal Motor Neuropathy, Autoimmune Nodopathies, Anti-Myelin Associated Glycoprotein Neuropathy, Chronic Inflammatory Sensory Polyradiculoneuropathy, and Chronic Ataxic Neuropathy with Ophthalmoplegia, M-Protein, Agglutinin, and Disialosyl Antibodies","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}